Medtronic plc MDT

Medtronic’s strongest current source fact is the 2026 annual filing itself: SEC EDGAR shows a 10-K filed on 2026-06-18, with revenue from contracts with customers of $36.36B, operating income of $6.47B, net income attributable to parent of $4.80B and diluted EPS of $3.73 for the period ending 2026-04-24. The daily story is therefore not built on rumour or chart embroidery. It starts with a fresh annual report and a June 3 Form 8-K that furnished the fourth quarter and fiscal year 2026 earnings press release.

Medtronic is an operating medical technology company, and the supplied product evidence keeps the equity tied to real devices rather than abstract ticker language. The 10-K names ENT products and systems including the Straightshot M5 microdebrider handpiece, Integrated Power Console system, NIM Vital nerve monitoring systems, Propel and Sinuva Sinus Implants, and StealthStation ENT and StealthStation FlexENT navigation systems. That matters because the filing story runs through product trust, clinical adoption, manufacturing cost and brand risk, not just a single headline profit number.

The balance sheet and cash rail are substantial but specific. For the 10-K period ending 2026-04-24, Medtronic reported assets of $93.03B, liabilities of $42.96B, stockholders' equity attributable to parent of $49.46B, cash and cash equivalents of $1.95B, short-term investments of $7.27B and net cash provided by operating activities of $7.33B. The same filing gives payments to acquire property, plant and equipment of $1.90B, inventory net of $5.95B, and an increase in inventories of $404.0M. Weighted average diluted shares were 1.29B.

No chart route or TradingView level is supplied in this evidence pack, so the market mechanism has to stay on the filing rail. The source route is SEC EDGAR: the 10-K, the June 3 earnings 8-K, the May 18 management-change 8-K, Form 4 filings dated June 8 and June 9, the filing index, submissions JSON and companyfacts JSON. That source route can verify filings, dates and reported figures; it does not prove intraday price behaviour, support, resistance, volume pressure or sentiment.

What changed in the named public record is clear enough. On May 18, 2026, Medtronic announced that Brett Wall would depart as Executive Vice President and President, Neuroscience Portfolio. On June 3, 2026, the company issued a press release announcing full year and fourth quarter fiscal 2026 financial results, furnished through Form 8-K. On June 18, the annual report and IRANNOTICE appeared on SEC EDGAR. Those are concrete events, not market chatter.

The unresolved part is also important. The supplied rail does not include guidance, segment growth figures, dividend detail, buyback amounts, analyst estimates, market share data, litigation updates beyond the named filing risk language, or a current price chart. A deeper daily file would need those rails before making claims about valuation pressure, operating momentum by division or the market’s live reaction.